Navigation Links
For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
Date:2/24/2009

SEATTLE, Feb. 24 /PRNewswire-USNewswire/ -- Many soldiers who experienced mild head trauma or a blast exposure while serving in Iraq or Afghanistan are returning to the United States with headaches, according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.

The study, conducted at Fort Lewis, WA, involved 978 U.S. Army soldiers returning from Iraq or Afghanistan in 2008. All had experienced a concussion, head injury or blast exposure while deployed.

Nearly 98 percent of the soldiers reported having headaches during the last three months of their deployment. The headaches started within one week of the traumatic brain injury for 37 percent of the soldiers, and within one to four weeks for 20 percent. Among the soldiers whose headaches started within a week of the injury, 60 percent had migraine-like headaches and 40 percent had headaches that interfered with their ability to do their daily activities. Thirty percent had headaches for 15 or more days each month.

"Mild traumatic brain injury is occurring in 15 to 25 percent of soldiers deployed to Iraq or Afghanistan," said study author Brett J. Theeler, MD, of Madigan Army Medical Center in Tacoma, WA, and a member of the American Academy of Neurology. "The associated headaches can be a source of impaired occupational functioning. These findings should alert health care providers, especially those affiliated with the military or veteran health care systems, to the need to identify and properly treat headaches among soldiers."

The study was supported by the Uniformed Services University of the Health Sciences through a grant from the Congressionally Directed Medical Research Program.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer's disease, narcolepsy, and stroke.

For more information about the American Academy of Neurology, visit www.aan.com.

The AAN 61st Annual Meeting, the world's largest gathering of neurology professionals, takes place April 25 to May 2, 2009, in Seattle. Visit www.aan.com/am for more information.

To access 2009 AAN Annual Meeting abstracts available February 25, 2009, visit http://www.aan.com/go/science/abstracts.

Late-breaking abstracts will be featured in press release at the 2009 AAN Annual Meeting in Seattle.


'/>"/>
SOURCE American Academy of Neurology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. First U.S. Patients Enrolled in the REALISM Continued Access Study
4. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
5. Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain
6. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
7. Diverse Approaches to Alzheimers Therapies Continue to Show Progress at ICAD
8. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
9. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
10. ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
11. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... Pace Analytical, a company of over 2,000 employees and a leader in environmental ... Sciences, further solidifying their position as the top American owned and operated environmental ... ... Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative full ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... The Ellis Agency, ... with the Epilepsy Foundation in a community wide charity event with the goal of ... Sunde, a young local woman who lives with epilepsy, recently launched a charity campaign ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
Breaking Medicine News(10 mins):